Google collecting personal data of millions in health project

Google is collecting one of the biggest troves of personal data in its healthcare initiative, known as “Project Nightingale,” with detailed information of millions of Americans, according to The Wall Street Journal.

Google has acquired the personal health information of millions by teaming up with one of the nation’s largest health systems, Ascension––and they’re keeping the project secret. Project Nightingale launched last year, and neither patient nor doctors have been notified that complete health histories––including patient names and dates of birth––have been collected, the WSJ reported.

The revelation by the news outlet brings patient privacy into a new light, as Google is using the information to build new software, but privacy laws under the Health Insurance Portability and Accountability Act (HIPAA) allow healthcare organizations to share patient data if it helps carry out their healthcare functions. And patients don’t have to be notified under HIPAA if their information is shared for those purposes.

The WSJ’s report also could put Amazon, Apple and Microsoft on notice, as they also continue to invest further in the healthcare space to make headway with critical healthcare data.

See the full story below:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.